'Targeted therapy' presentation slideshows

Bayesian Adaptive Designs for Targeted Therapy Development for Cancer and Beyond

University of Pennsylvania Annual Conference on Statistical Issues in Clinical Trials: Statistical Issues in Targeted Therapies. Bayesian Adaptive Designs for Targeted Therapy Development for Cancer and Beyond. J. Jack Lee, Ph.D. Department of Biostatistics University of Texas

986 views • 65 slides

Chronic Leukemias

Chronic Leukemias. Chronic Leukemias. CLL CML CMML. Normal CBC with lymphocyte. Chronic Leukemias. CLL CML CMML. Chronic Leukemias. CLL- Chronic Lymphocytic CML CMML. Chronic Leukemias. CLL incidence 4:100,000 Male to Female 2:1 age <65 Mean age 72 Less than 3% in age <45

738 views • 54 slides

New Developments in the Management of Advanced Breast Cancer

New Developments in the Management of Advanced Breast Cancer. Including Updates from ASCO 2007. Supported by an educational grant from Roche Laboratories. Jointly Sponsored by:. Course Objectives. At the conclusion of this course, participants should be able to:

567 views • 49 slides

576 views • 42 slides

Optimal Sequence of Therapies for Advanced GI Neuroendocrine Tumors (NET)

Optimal Sequence of Therapies for Advanced GI Neuroendocrine Tumors (NET). Tim Hobday M.D. Mayo Clinic Rochester, MN. Disclosure. Research funding: Novartis. Off-label therapy discussed. Octreotide for PNET Temozolomide and capecitabine for PNET Targeted therapy for carcinoid tumors

610 views • 39 slides

Cancer Education Slides

Cancer Education Slides. Kidney Cancer. 2009. What is Cancer?. A group of 100 different diseases The uncontrolled, abnormal growth of cells Cancer may spread to other parts of the body. What is Kidney Cancer?. An estimated 57,760 people diagnosed in the United States in 2009

542 views • 32 slides

Targeted Therapy for Renal Cell Cancer

Targeted Therapy for Renal Cell Cancer. Dr.Mahmoodzadeh Oncologist-Hematologist. Kidney Neoplasms. Primary or Secondary (metastatic) Renal cell carcinoma (RCC) represents 80-85% of primary renal neoplasms Transitional cell carcinoma 8% Rare tumors include: - Oncocytomas

858 views • 31 slides

Acute Leukemia

Acute Leukemia. Treatment. PREPARATION. 1- Acute leukemia should be regarded as an emergency & needs treatment within 48h of Dx 2- Patient should be prepared for treatment to avoid complications 3- Stabilization of patient & ttt of complications 4- Taking consent of patient or family.

585 views • 29 slides

Andrew Poklepovic MD Massey Cancer Center Hematology, Oncology, and Palliative Care

Approaching Personalized Oncology as a Clinician and Researcher Where are we now, and how can we take it further?. Andrew Poklepovic MD Massey Cancer Center Hematology, Oncology, and Palliative Care Associate Member Developmental Therapeutics Program.

431 views • 26 slides

Breast Cancer: Updates in systemic therapy options

Breast Cancer: Updates in systemic therapy options. Hope Qamoos, NP Breast Oncology Stanford Hospital and Clinics. Breast Cancer: Updates in systemic therapy options Course Objectives. Identify the treatment options available to treat the following subtypes of breast cancer

445 views • 22 slides

Biological and Molecular Targeted Therapy for HHC

Biological and Molecular Targeted Therapy for HHC. Sheng-Long Ye, MD, PhD Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai, China. Problem in HCC. Severe cirrhosis Intrahepatic spread and distant metastasis Low resectability High postoperative recurrence.

456 views • 21 slides

Cytoreductive nephrectomy in the targeted therapy era

Cytoreductive nephrectomy in the targeted therapy era. ????? 6. At presentation 25% will have locally advanced or mts 20-30% of local disease will progress to advanced disease despite surgical excision Poor Survival. Natural history of RCC. Treatment of metastatic RCC.

468 views • 20 slides

Prostate Cancer

321 views • 17 slides

Targeted Therapy: Anti-EGFR Treatment

Targeted Therapy: Anti-EGFR Treatment. January 27, 2006 Frankfurt am Main Germany. Targeted Therapy: Anti-EGFR Treatment. Moderator Jeffrey Myers M.D. Ph.D. Speaker Jan Vermorken M.D. Ph.D. Panelists Marshall Posner M.D. Wilfried Budach M.D. Jens Overgaard M.D.

446 views • 16 slides

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumors

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumors. Introduction Tim Butler March 8 th , 2012. Topics for Today. GI Stromal Tumors (GIST) KIT Signaling KIT targeted therapy ETV1. Interstitial Cells of Cajal. Discovered by Ramon Cajal

348 views • 14 slides

Perugia: Etruscan Arch

Perugia: Etruscan Arch. Perugia: Town Hall and Fountain. Perugia: University Medical Center. Visit of Dr. James Smith and his wife to our medical center. HAIRY CELL LEUKEMIA AS A PARADIGM FOR DEVELOPMENT OF NEW THERAPIES. Mutated BRAF (targeted therapy ?). Pentostatin Cladribin.

306 views • 13 slides

Sino-Danish Breast Cancer Research Centre

205 views • 11 slides

1.08k views • 11 slides

Sino-Danish Breast Cancer Research Centre

217 views • 11 slides

Cancer Treatments

Cancer Treatments. Jessica Davies and Connie Holm. Surgery. Surgery can be used to diagnose, treat, or even help prevent cancer in some cases. Most people with cancer will have some type of surgery.

334 views • 10 slides